Literature DB >> 570997

Erythropoietin levels in uremic nephric and anephric patients.

J Caro, S Brown, O Miller, T Murray, A J Erslev.   

Abstract

Erythropoietin titers were measured in anemic nephric and anephric patients undergoing chronic hemodialysis by utilizing a plasma concentration technique. In eight out of 11 anephric patients studied, decreased but detectable levels of erythropoietin were found, suggesting that extrarenal erythropoietin plays a role in the regulation of red cell production in anephric patients. In 14 nephric uremic patients, erythropoietin production was found to be more variable, with one group of eight patients having erythropoietin levels in the range for normal nonanemic individuals (3.9 to 15 mU/ml), and a second group of six patients with erythropoietin higher than normal (greater than 15 mU/ml). Both groups were found to be equally anemic, indicating that in the second group the bone marrow is less responsive to erythropoietin. The severity of secondary hyperparathyroidism was found to be higher in this second group, suggesting a role of PTH in the bone marrow unresponsiveness. A good correlation between biological and immunological erythropoietin activities was found in the plasma from normal subjects and uremic nephric and anephric patients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 570997

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  27 in total

1.  Darbepoetin alfa for the treatment of anemia in pediatric patients with chronic kidney disease.

Authors:  Bradley A Warady; Mazen Y Arar; Gary Lerner; Arline M Nakanishi; Catherine Stehman-Breen
Journal:  Pediatr Nephrol       Date:  2006-05-25       Impact factor: 3.714

2.  Population pharmacokinetics of darbepoetin alpha in peritoneal dialysis and non-dialysis patients with chronic kidney disease after single subcutaneous administration.

Authors:  Kazuki Kawakami; Hirotaka Takama; Daisuke Nakashima; Hideji Tanaka; Eiji Uchida; Tadao Akizawa
Journal:  Eur J Clin Pharmacol       Date:  2008-09-21       Impact factor: 2.953

Review 3.  Erythropoietin: an old friend revisited.

Authors:  H Hambley; G J Mufti
Journal:  BMJ       Date:  1990-03-10

4.  Erythropoietin neuroprotection with traumatic brain injury.

Authors:  Lucido L Ponce; Jovany Cruz Navarro; Osama Ahmed; Claudia S Robertson
Journal:  Pathophysiology       Date:  2012-03-14

5.  Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm.

Authors:  I C Macdougall; R D Hutton; I Cavill; G A Coles; J D Williams
Journal:  BMJ       Date:  1990-03-10

6.  Erythropoietin: the developing story.

Authors:  P M Cotes
Journal:  Br Med J (Clin Res Ed)       Date:  1988-03-19

7.  Pharmacokinetics of epoetin in haemodialysis patients after subcutaneous administration: influence of chronic treatment.

Authors:  J P Schouten; G Voorhorst; A R Helbing; J W Janssen; P P Diderich; C T Op de Hoek
Journal:  Pharm World Sci       Date:  1993-12-17

8.  Red cell lipid peroxidation and antioxidant system in haemodialysed patients: influence of recombinant human erythropoietin (r-HuEPO) treatment.

Authors:  M Boran; C Küçükaksu; M Balk; S Cetin
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

9.  Identification of spermine as an inhibitor of erythropoiesis in patients with chronic renal failure.

Authors:  H W Radtke; A B Rege; M B LaMarche; D Bartos; F Bartos; R A Campbell; J W Fisher
Journal:  J Clin Invest       Date:  1981-06       Impact factor: 14.808

Review 10.  Erythropoietin.

Authors:  H Franklin Bunn
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.